Experts, Liberal MP hope for full ban on sports betting ads as advocates cite mental health decline

This article is new today!

Source: CBC Politics
Date: 2026-10-30 14:50:39.0
Tags: [National, Ontario, Alberta, Quebec, Healthcare, Social Services, Governance]

Bill S-211, introduced in May 2025 by Senator Marty Deacon and sponsored in the House by MP Bardish Chagger, is currently before the House standing committee on Canadian heritage to restrict sports betting ads across Canada. Supporters including Liberal MP Michael Coteau and public policy think-tank Cardus cite a University of Toronto study showing gambling-related emergency room visits nearly doubled in Ontario, alongside a 161 per cent increase in helpline calls among males aged 15-24 since single-game betting was legalized in 2021. Provincial officials from Ontario, Alberta, and Quebec, along with the Canadian Association of Broadcasters, have raised concerns regarding provincial jurisdiction, overlapping regulations, and economic impacts on commercial operators like FanDuel, DraftKings, and BetMGM.

Ontario Clarifies Longstanding Out-of-Country Drug Funding Process

Source: Ontario - Ministry of Health
Date: 2026-10-06 21:00:00.0
Tags: [Ontario, Healthcare, Affordability, Governance, Finance]

The Government of Ontario has amended Regulation 552 of the Health Insurance Act to align with its longstanding out-of-country drug funding policy, restricting out-of-country funding to treatments where the drug and administration are publicly funded in Ontario, temporarily unavailable locally, and necessary to prevent death or irreversible tissue damage. According to the Ministry of Health led by Minister Sylvia Jones, the regulatory clarification aims to prevent global pharmaceutical companies from bypassing direct price negotiations with the province and avoids potential health-care system cost increases of up to $5.2 billion annually alongside $170 million in out-of-country treatment requests. This follows a recent Ontario Divisional Court decision concerning out-of-country drug funding, which the government is evaluating alongside options such as an appeal or a negotiated resolution with the applicant.